Literature DB >> 11127420

Abstinence symptoms during withdrawal from chronic marijuana use.

E M Kouri1, H G Pope.   

Abstract

Although marijuana is the most commonly used illicit drug in the United States, it is not established whether withdrawal from chronic use results in a clinically significant abstinence syndrome. The present study was conducted to characterize symptoms associated with marijuana withdrawal following chronic use during a supervised 28-day abstinence period. Three groups of participants were studied: (a) current chronic marijuana users, (b) former chronic marijuana users who had not used marijuana for at least 6 months prior to the study, and (c) marijuana nonusers. Current users experienced significant increases in anxiety, irritability, physical tension, and physical symptoms and decreases in mood and appetite during marijuana withdrawal. These symptoms were most pronounced during the initial 10 days of abstinence, but some were present for the entire 28-day withdrawal period. These findings support the notion of a marijuana withdrawal syndrome in humans.

Entities:  

Mesh:

Year:  2000        PMID: 11127420     DOI: 10.1037//1064-1297.8.4.483

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  59 in total

Review 1.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

2.  Incremental validity of anxiety sensitivity in relation to marijuana withdrawal symptoms.

Authors:  Marcel O Bonn-Miller; Michael J Zvolensky; Erin C Marshall; Amit Bernstein
Journal:  Addict Behav       Date:  2006-12-19       Impact factor: 3.913

3.  A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances.

Authors:  R G Vandrey; A J Budney; J R Hughes; A Liguori
Journal:  Drug Alcohol Depend       Date:  2007-07-23       Impact factor: 4.492

4.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

5.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

6.  DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults.

Authors:  Ofir Livne; Dvora Shmulewitz; Shaul Lev-Ran; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2018-10-22       Impact factor: 4.492

Review 7.  Substitution and Complementarity of Alcohol and Cannabis: A Review of the Literature.

Authors:  Meenakshi Sabina Subbaraman
Journal:  Subst Use Misuse       Date:  2016-06-01       Impact factor: 2.164

Review 8.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

Review 9.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

10.  Substance use disorders: Relationship with intermittent explosive disorder and with aggression, anger, and impulsivity.

Authors:  Emil F Coccaro; Daniel J Fridberg; Jennifer R Fanning; Jon E Grant; Andrea C King; Royce Lee
Journal:  J Psychiatr Res       Date:  2016-06-16       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.